Close

Johnson & Johnson’s single-dose COVID-19 vaccine gets approval for emergency use in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

CDSCO to Introduce Integrated Drug Regulatory Platform in 18 Months

The Central Drugs Standard Control Organisation (CDSCO) has announced...

Resilience and Eli Lilly Expand Strategic Partnership with $750 Million Ohio Manufacturing Investment

Resilience has announced an expansion of its strategic partnership...
- Advertisement -

Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine was on Saturday granted approval for emergency use in India. “India expands its vaccine basket. Johnson and Johnson’s single-dose Covid-19 vaccine is given approval for Emergency Use in India,” health minister Mansukh Mandaviya tweeted on Saturday. This is the fifth Covid-19 vaccine to be given emergency use approval in India and would further boost the nation’s collective fight against Covid-19, the minister said.

J&J had a week ago withdrawn its application for carrying out phase-3 clinical trials in India for its vaccine. This was after the Indian government waived this requirement for vaccines that had approvals from regulatory bodies in the US, UK, Europe and Japan. This was done to fast-track the vaccine approval process in the country and accelerate vaccination.

The country already has four vaccines approved so far, including Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V and Moderna, making J&J the fifth one. Moderna is yet to launch their vaccine in India. In India, J&J have a tie up with Biological E for technology transfer and manufacturing the Covid-19 vaccine in India.

J&J had been given emergency use authorisation by the US FDA in February this year. J&H also has Conditional Marketing Authorisation Application from the European Commission and got an Emergency Use Listing from the World Health Organization for its Covid-19 vaccine.

This single vaccine has been developed by the Janssen Pharmaceutical Companies of J&J. The J&J Covid-19 single-dose vaccine has to be stored at 2-8°C. According to J&J, their single-shot Covid-19 vaccine had demonstrated strong neutralising antibody activity against the rapidly spreading Delta variant . This variant is dominant in India. Their data showed that the durability of the immune response lasted through at least eight months. Overall the vaccine had an efficacy of 85% against severe and critical Covid-19 disease.

The country on Saturday crossed the 50-crore mark in vaccination administration. There were 38,628 daily new cases reported in the country taking the active case load to 4.12 lakh cases with a daily case positivity rate of 2.21%.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

CDSCO to Introduce Integrated Drug Regulatory Platform in 18 Months

The Central Drugs Standard Control Organisation (CDSCO) has announced...

Resilience and Eli Lilly Expand Strategic Partnership with $750 Million Ohio Manufacturing Investment

Resilience has announced an expansion of its strategic partnership...

WHO Introduces Global Regulatory Framework for Decarbonizing Pharmaceuticals

The World Health Organization (WHO) has officially launched the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »